Dabrafenib
Adjuvant
Small moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the Adjuvant cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Taiho Oncology, Inc. | Phase 3 | B |
CIS-DIAMMINEDICHLOROPLATINUM II Taiho Oncology, Inc. | Phase 3 | B |
Zipalertinib Taiho Oncology, Inc. | Phase 3 | B |
INTERFERON ALFA-2B Dermatologic Cooperative Oncology Group | Phase 3 | B |
Docetaxel Fudan University | Phase 2/3 | B |
View all 12 →
Same molecule, other indications
Dabrafenib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →